S1925
OPEN TO ACCRUAL
Ph 3 Early Txt vs Late Txt of Venetoclax and Obinituzumab for Pts with High-Risk Cll/Sll
UW21051
OPEN TO ACCRUAL
Phase 1/2 Study LY3537982 in pts w/KRAS G12-C-Mutant Advanced Solid Tumors
UW22069
OPEN TO ACCRUAL
PH 2 Study MK-2140 in pts with Aggressive and Indolent B-Cell Malignancies
UW22087
OPEN TO ACCRUAL
Phase II Study of Venetoclax-Obinutuzumab Retreatment in Patients with Recurring CLL
UW23124
OPEN TO ACCRUAL
Ph 3 Study of MK-1026 vs Investigator's Choice of Ibrutinib or Acalabrutinib in untreated CLL/SLL